1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
GeneThera, Inc.

GeneThera, Inc.

GTHR
GeneThera, Inc.US flagOther OTC
0.00
USD
-NaN
- -
3,533.00Market Cap
GeneThera, Inc.
GTHR
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
FRC
32.72
9.7
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-323.42
-83.39
-2.93
-0.1
-0.02
-0.05
-0.07
-0.04
-0.02
-0.03
-0.02
-0.02
-0.09
-0.01
-0.04
-0.04
-0.02
Basic EPS, GAAP
-52.77
-1.79
-0.07
- -
- -
-0.02
-0.03
- -
- -
-0.01
- -
- -
-0.01
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3,388.41
-1,620.43
-37.14
-1.43
-0.87
-0.84
-0.89
-0.81
-0.73
-0.68
-0.67
-0.66
-0.78
-0.85
-1.54
-1.27
-0.96
Book Value per Share
-223.83
-132.79
-3.31
-0.16
-0.12
-0.12
-0.18
-0.18
-0.18
-0.18
-0.18
-0.18
-0.17
-0.19
-0.38
-0.32
-0.25
Tangible Book Value per Share
- -
- -
- -
13
22
24
25
29
33
37
39
40
38
36
20
25
34
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-988.38
-843.67
-12,872.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-1
-1
-1
-1
- -
-1
-2
-1
-1
-1
-1
-1
-3
-1
-1
-1
-1
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-988.38
-859.89
-12,872.14
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-1
-2
-1
-2
-3
-3
-5
-5
-6
-7
-7
-7
-6
-7
-8
-8
-9
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
-1
-1
-2
-2
-3
-3
-5
-5
-6
-7
-7
-7
-6
-7
-8
-8
-9
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
35
35
Market Capitalization
1
1
1

Working Capital

FRC

•

in mil. unless spec.
Mar'22
Jun'22
Sep'22
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
8
8
9
Payables & Accruals
7
8
8
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.39%
3.09%
6.41%
Free Cash Flow
-185.91%
-373.32%
61.48%
Net Income, GAAP
38.49%
68.19%
30.6%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
-0.01
-0.01
- -
-0.04
2021
-0.01
-0.01
-0.01
- -
-0.04
2022
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Similar Companies
Sareum Holdings plc (SAR.L)
Verastem, Inc. (0LOV.L)
Oncolys BioPharma Inc. (4588.T)
MapLight Therapeutics, Inc. (MPLT)
ImmuPharma PLC (IMM.L)
Aeterna Zentaris Inc. (AEZS.TO)
Business
GeneThera, Inc. (OTC: GTHR) develops genetics-based diagnostic assays, vaccine solutions, molecular diagnostic tests, therapeutics, and vaccines focused on controlling zoonotic infections that spread from animals to humans. The company offers the Molecular Robotic/AI Laboratory Platform (MORAP) integrating advanced robotic systems with artificial intelligence for automated testing; MORAPAT to prevent animal-to-human disease transmission; large-scale production processes for highly purified, high-titer Adenovirus and Adeno-associated virus (AAV) vectors; Adenovirus- and AAV-based recombinant DNA vaccines targeting zoonotic pathogens; and PURIVAX, a purification system enhancing biological purity and viral titer of these vectors. It targets the biotechnology sector, serving animal health markets including dairy, livestock, and food safety applications to detect pathogens like Mycobacterium avium paratuberculosis (MAP) linked to Johne's disease in cattle and potential Crohn's disease in humans. Founded in 1998 by Antonio Milici and headquartered in Westminster, Colorado, the company operates primarily in the United States with two employees and explores global laboratory networks. Recent developments include a 2015 exclusive worldwide collaboration with Hudson Robotics to advance Integrated Automated Robotic Systems for tuberculosis and paratuberculosis testing, granting Hudson 10% equity; earlier efforts to pursue revenue-generating acquisitions via advisor Mezey Howarth; and ongoing status as a development-stage firm with no recent revenue or financial reporting updates amid highly speculative micro-cap trading.